Xiaojing J. Zhang

Shenyang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.

Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)
Published: August 18, 2025

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

Journal: Nature communications
Published: January 31, 2024

Quality of life issues in patients with bone metastases: A systematic review.

Quality of life issues in patients with bone metastases: A systematic review.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: October 30, 2023

[Retracted] Ursolic acid suppresses the biological function of osteosarcoma cells.

[Retracted] Ursolic acid suppresses the biological function of osteosarcoma cells.

Journal: Oncology letters
Published: June 19, 2023

CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis.

CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis.

Journal: Molecular cancer
Published: September 15, 2021

The clinical predictors for the prognosis of patients with osteosarcoma

The clinical predictors for the prognosis of patients with osteosarcoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: May 26, 2021

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.

Journal: Frontiers in oncology
Published: April 18, 2021

Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.

Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.

Journal: Aging
Published: October 11, 2019

PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes.

PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes.

Journal: DNA and cell biology
Published: September 20, 2019

Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1.

Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1.

Journal: Aging
Published: August 02, 2019

Extracellular nanovesicles-transmitted circular RNA has_circ_0000190 suppresses osteosarcoma progression.

Extracellular nanovesicles-transmitted circular RNA has_circ_0000190 suppresses osteosarcoma progression.

Journal: Journal of cellular and molecular medicine
Published: June 10, 2019

Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.

Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.

Journal: Cell cycle (Georgetown, Tex.)
Published: May 23, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026